Avanos Medical (NYSE:AVNS – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.050-1.250 for the period, compared to the consensus estimate of 1.670. The company issued revenue guidance of $665.0 million-$685.0 million, compared to the consensus revenue estimate of $713.1 million.
Avanos Medical Price Performance
Shares of AVNS opened at $15.54 on Wednesday. Avanos Medical has a twelve month low of $14.98 and a twelve month high of $25.36. The firm has a market capitalization of $714.36 million, a price-to-earnings ratio of 45.71 and a beta of 0.98. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The firm’s fifty day simple moving average is $16.15 and its 200-day simple moving average is $19.73.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut Avanos Medical from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 3rd.
Avanos Medical Company Profile
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Featured Articles
- Five stocks we like better than Avanos Medical
- How to Choose Top Rated Stocks
- Tempus AI Is a Buy, If You Can Handle the Volatility
- The 3 Best Fintech Stocks to Buy Now
- Massive Buybacks: 3 Stocks Returning Big Cash to Shareholders
- Profitably Trade Stocks at 52-Week Highs
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.
